ClinicalTrials.gg
Active, not recruitingNCT06941792V-INVINCIBLEUpdated May 29, 2026

Inclisiran Effectiveness in China: a Pragmatic Randomized Trial

A Phase 4 interventional study of inclisiran sodium injection and Standard of Care in Coronary Heart Disease, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 19 sites in China. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,590
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 223 studies in Coronary Disease with a site in China — 68 open to participants now, 77 under way, 3 of them phase 3. Coronary Disease · China.

Enrollment
25th of 141
1,590 · median 220
Started
2025
with 19 others
Phase 4
34 of 223
6 open now
Primary completion
2027-04
later than 52 of 76 live
Registered
186th of 223
by date

Among the 223 studies in Coronary Disease with a site in China, this one is the 25th largest by enrollment of the 141 interventional ones that give a count, is one of 20 that started in 2025, is one of 34 in phase 4, reaches primary completion later than 52 of the 76 other live ones, and was the 186th registered.

Coronary Disease

1,521 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

68 of the 223 studies in Coronary Disease with a site in China are open now. Recruiting first, the newest first:

63 more — sign in →

All 68 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 105 Coronary Disease studies recruiting now, 63 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 223 studies in Coronary Disease with a site in China, or all of them as a file.
02

Study summary

The current study will be conducted to evaluate the real-world effectiveness of inclisiran relative to standard of care (SoC) in Chinese patients with coronary heart disease (CHD), not only with the low-density lipoprotein cholesterol (LDL-C) change in 1 year, but also the LDL-C Test on Target for 1 year. This study further aims to assess the adherence, treatment patterns and satisfaction, and safety of inclisiran among Chinese patients.

Read the detailed description

The study is a multicenter, randomized, parallel, open-label, pragmatic trial, to assess the effectiveness of inclisiran in the real-world compared to SoC, in patients with CHD in China who did not achieve LDL-C goal despite maximally tolerated statin therapy for ≥4weeks stable using. CHD patients include patients with acute coronary syndrome and patients with chronic coronary syndrome.

After granting informed consent, being screened, and confirmed eligible for the study, participants will be randomized to 2 arms (inclisiran or SoC) in a 1:1 ratio.

Following the randomization, participants start inclisiran or SoC adaptation (which means switching to or adding on another/other lipid-lowering therapies (LLT[s]). This start date is defined as Day 0.

During follow-up, each participant will follow routine care, and the results of LDL-C tests will be collected for each Visit (every 3 months), with an allowable window of ±1.5 months. Each patient will be followed up until his/her end of study (EOS), which is the earliest of the end of follow-up period (Visit 4: approximately 12 months following Day 0), lost to follow-up, consent withdrawal, death, and participating in another interventional trial.

03

Conditions studied

  • Coronary Heart Disease

Browse trials for

Keywords

  • Inclisiran
  • effectiveness
  • lipid-lowering
  • low-density lipoprotein cholesterol Test on Target
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed must be obtained prior to participation in the study
  2. Documented diagnosis of CHD prior to screening, including acute coronary syndrome (ACS) and chronic coronary syndrome (CCS)
  3. Aged ≥18 years at randomization
  4. Despite maximally tolerated statin therapy for ≥4weeks stable using prior to screening, LDL-C result at screening not at goal (≥1.8 mmol/L).

The maximum tolerated dose of statins also includes patients with statin intolerance or .

Exclusion criteria

Exclusion Criteria:

  1. Received inclisiran during the 2 years prior to the screening.
  2. Received proprotein convertase subtilisin-kexin type 9 (PCSK9) mabs during the 3 months prior to screening.
  3. Participating in an interventional trial at enrollment
  4. Having severe liver disorder ( class C)
  5. Any other condition that may put the participant at significant risk if the participant participate in the current study, according to investigator's (or delegate's) judgment.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,590 participants (actual)

Study arms

  • Experimental
    inclisiran group

    patients in the inclisiran group will receive inclisiran (may or may not plus cholesterol absorption inhibitor at the discretion of the treating physician).

    Drug: inclisiran sodium injection

  • Active comparator
    Standard of Care group

    Patients in the SoC group will switch to/add on another/other LLT(s) at the discretion of the treating physician, as long as it is not inclisiran or an investigational drug.

    Combination Product: Standard of Care

Interventions

  • After randomization, patients in the inclisiran group will receive inclisiran sodium injection

  • Combination productStandard of Care

    After randomization switching to or adding on another/other lipid-lowering therapies

06

What researchers measure

Primary outcomes

  1. The percentage change in low-density lipoprotein cholesterol (LDL-C) level from baseline at 12 months, for the inclisiran group versus the standard of care (SoC) group

    To evaluate the real-world effectiveness of inclisiran, on the change in LDL-C levels at Month 12, compared with SoC, in Chinese patients with coronary heart disease (CHD)

    Time frame: 12 months

Secondary outcomes

  1. The proportion of participants with the 1-year LDL-C Test on Target ≥75%, for the inclisiran group versus the SoC group

    To evaluate the real-world effectiveness of inclisiran, on the LDL-C Test on Target at Month 12, compared with SoC, in Chinese patients with CHD

    Time frame: 12 months

  2. The percentage change in LDL-C level from baseline at 3 months, 6 months, and 9 months, for the inclisiran group versus the SoC group

    To evaluate the effectiveness of inclisiran on the change in LDL-C levels at Month 3, Month 6, and Month 9, compared with SoC

    Time frame: At Month 3, Month 6 and Month 9

  3. The proportion of participants with LDL-C <1.8 mmol/L at 12 months, for the inclisiran group versus the SoC group

    To evaluate the effectiveness of inclisiran on LDL-C at goal at Month 12

    Time frame: 12 months

  4. To describe LDL-C Test on Target value during the 12 months after baseline, for the inclisiran group and the SoC group.

    To evaluate the real-world effectiveness of inclisiran, on LDL-C Test on Target at 1 year, compared with the SoC group.

    Time frame: 12 months

  5. The percentage change in levels of total cholesterol, triglyceride, HDL-C, Lp(a), ApoA, and ApoB, from baseline at 3 months, 6 months, 9 months, and 12 months, for the inclisiran group versus the SoC group

    To evaluate the effectiveness of inclisiran on the change in other parameters of the lipid profile at Month 3, Month 6, Month 9, and Month 12, compared with SoC

    Time frame: At Month 3, Month 6, Month 9, and Month 12

  6. Area under the curve (AUC) of LDL-C level versus time (from 0 months to 12 months), for the inclisiran group versus the SoC group

    To evaluate the accumulated LDL-C in the inclisiran group and the SoC group

    Time frame: Baseline, 12 months

  7. The proportion of participants with PDCinclisiran≥80% in the inclisiran group and the proportion of participants with PDCnon-statin≥80% in the SoC group, at 3 months, 6 months, 9 months, and 12 months

    To estimate the adherence to inclisiran and other non-statin lipid-lowering therapies (LLTs), as measured by the proportion of days covered (PDC), using prescription data

    Time frame: At Month 3, Month 6, Month 9, and Month 12

  8. The average number of days covered, of inclisiran in the inclisiran group and of non-statin lipid-lowering therapies (LLTs) in the SoC group, at 3 months, 6 months, 9 months, and 12 months

    To estimate the adherence to inclisiran and other non-statin lipid-lowering therapies (LLTs), as measured by the proportion of days covered (PDC), using prescription data

    Time frame: At Month 3, Month 6, Month 9, and Month 12

  9. The average PDCinclisiran in the inclisiran group and the average PDCnon-statin in the SoC group, at 3 months, 6 months, 9 months, and 12 months

    To estimate the adherence to inclisiran and other non-statin lipid-lowering therapies (LLTs), as measured by the proportion of days covered (PDC), using prescription data

    Time frame: At Month 3, Month 6, Month 9, and Month 12

  10. Age at randomization and age at first diagnosis of CHD

    To describe the demographics and clinical characteristics of the inclisiran group and the SoC group.

    Time frame: 12 months

  11. Sex

    To describe the demographics and clinical characteristics of the inclisiran group and the SoC group

    Time frame: 12 months

  12. Temperature

    To describe the demographics and clinical characteristics of the inclisiran group and the SoC group

    Time frame: 12 months

  13. Respiratory rate

    To describe the vital signs characteristics of inclisiran group and the SoC group. It will be measured manually or with an electrocardiogram monitor.

    Time frame: 12 months

  14. Blood pressure

    To describe the demographics and clinical characteristics of the inclisiran group and the SoC group

    Time frame: 12 months

  15. Heart rate

    To describe the demographics and clinical characteristics of the inclisiran group and the SoC group

    Time frame: 12 months

  16. Previous lipid-lowering therapies (LLTs), through Adherence Assessment Questionnaire (AAQ)

    The AAQ is a generic instrument for assessing non-adherence (NA) in chronic conditions, consists of 11 items in total. Ten of these items are phrased as statements and use a 4-point Likert scale, offering the response options: Strongly agree, Generally agree, Generally disagree, and Strongly disagree. Each item is scored from 1 to 4, with a higher score indicating a greater likelihood of non-adherence.

    Time frame: 12 months

  17. Previous lipid-lowering therapies (LLTs), through Adherence Barriers Questionnaire (ABQ)

    The ABQ consists of 16 items, each addressing a specific adherence barrier. All items are formulated as statements. A 4-point Likert scale is used, deliberately omitting a neutral response option to encourage decisive answers. The available response options are: Strongly agree, Generally agree, Generally disagree, and Strongly disagree. Each response is assigned a value from 1 to 4 or 4 to 1, depending on the wording of the item, ensuring that a higher score reflects a stronger influence of a specific barrier on the patient's perception. The total score ranges from 16 (minimum) to 64 (maximum).Based on patient responses, both a general ABQ score and item- or subscale-specific scores can be calculated, indicating the number and strength of adherence barriers experienced by a patient.

    Time frame: 12 months

  18. Dose, frequency, and treatment duration of inclisiran in the inclisiran group and of other LLTs in the SoC group

    To describe the treatment patterns of inclisiran and other LLTs

    Time frame: 12 months

  19. LDL-C variability in the inclisiran group by average successive variability (ASV), coefficient of variation (CV), and variation independent of mean (VIM)

    To evaluate LDL-C variability in the inclisiran group

    Time frame: 12 months

  20. Subsequent LLTs for participants who discontinued/switched the assigned treatment

    To describe the treatment patterns of inclisiran and other LLTs

    Time frame: 12 months

  21. Concomitant lipid lowering treatments

    To describe the treatment patterns of inclisiran and other LLTs

    Time frame: 12 months

  22. Treatment satisfaction from Treatment Satisfaction Questionnaire for Medication (TSQM)

    This scale includes four dimensions: drug treatment effectiveness, adverse reactions, convenience, and overall satisfaction. Whether the patient has experienced adverse drug reactions is scored using "yes" and "no"; The adverse reaction dimension is evaluated using a Likert-5 scale, with scores ranging from 1 to 5 indicating "extremely dissatisfied" to "not dissatisfied at all"; The effectiveness, convenience, and overall satisfaction are rated on a Likert-7 scale, with scores ranging from 1 to 7 indicating "extremely dissatisfied" and "extremely satisfied", respectively. The standard score for each dimension is 100 points, and the higher the score, the higher the patient's satisfaction with drug treatment.

    Time frame: At Month 6 and Month 12

  23. The average PDCinclisiran in the inclisiran group and the average PDCnon-statin in the SoC group, from patient questionnaire data, at 3 months, 6 months, 9 months, and 12 months

    To assess treatment satisfaction and adherence by questionnaires

    Time frame: At Month 3, Month 6, Month 9, and Month 12

  24. Incidence of adverse events (AEs), serious adverse events (SAEs)

    To evaluate the safety of Inclisiran

    Time frame: 12 months

  25. Number of participants with relevant medical history

    To describe the demographics and clinical characteristics of the inclisiran group and the SoC group

    Time frame: 12 months

07

Study locations

19 sites
  • Novartis Investigative Site
    Anqing, Anhui 246003, China
  • Novartis Investigative Site
    Beijing, Beijing Municipality 102218, China
  • Novartis Investigative Site
    Chongqing, Chongqing Municipality 400010, China
  • Novartis Investigative Site
    Longyan, Fujian 364099, China
  • Novartis Investigative Site
    Jiamusi, Heilongjiang 154002, China
  • Novartis Investigative Site
    Zhengzhou, Henan 451400, China
  • Novartis Investigative Site
    Baotou, Inner Mongolia 014010, China
  • Novartis Investigative Site
    Shenyang, Liaoning 110016, China
  • Novartis Investigative Site
    Shenyang, Liaoning 121100, China
  • Novartis Investigative Site
    Jining, Shandong 272000, China
  • Novartis Investigative Site
    Weifang, Shandong 261000, China
  • Novartis Investigative Site
    Shanghai, Shanghai Municipality 200065, China
  • Novartis Investigated Site
    Taiyuan, Shanxi 030000, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610031, China
  • Novartis Investigative Site
    Ürümqi, Xinjiang Uygur Autonomous Region 830054, China
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310007, China
  • Novartis Investigative Site
    Jinhua, Zhejiang 321000, China
  • Novartis Investigative Site
    Ningbo, Zhejiang 315000, China
  • Novartis Investigative Site
    Wenzhou, Zhejiang 325000, China
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Apr 2027, 22 months after the start.

Of 26 phase 4 interventional studies under Coronary Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 58. This study's planned 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2025
First posted
Apr 24, 2025
StartActual
Jun 17, 2025
Primary completionEst.
Apr 30, 2027
CompletionEst.
Apr 30, 2027
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06941792
Responsible party
Sponsor
First posted
Apr 24, 2025
Start date
Jun 17, 2025
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
May 29, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inclisiran

Start the discussion